Stock Research for EXEL

EXEL

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

EXEL Stock Chart & Research Data

The EXEL chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the EXEL chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


EXEL Due diligence Resources & Stock Charts

The EXEL stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View EXEL Detailed Price Forecast - CNN Money CNN View EXEL Detailed Summary - Google Finance
Yahoo View EXEL Detailed Summary - Yahoo! Finance Zacks View EXEL Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View EXEL Trends & Analysis - Trade-Ideas Barrons View EXEL Major Holders - Barrons
NASDAQ View EXEL Call Transcripts - NASDAQ Seeking View EXEL Breaking News & Analysis - Seeking Alpha
Spotlight View EXEL Annual Report - CompanySpotlight.com OTC Report View EXEL OTC Short Report - OTCShortReport.com
TradeKing View EXEL Fundamentals - TradeKing Charts View EXEL SEC Filings - Bar Chart
WSJ View Historical Prices for EXEL - The WSJ Morningstar View Performance/Total Return for EXEL - Morningstar
MarketWatch View the Analyst Estimates for EXEL - MarketWatch CNBC View the Earnings History for EXEL - CNBC
StockMarketWatch View the EXEL Earnings - StockMarketWatch MacroAxis View EXEL Buy or Sell Recommendations - MacroAxis
Bullish View the EXEL Bullish Patterns - American Bulls Short Pains View EXEL Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View EXEL Stock Mentions - StockTwits PennyStocks View EXEL Stock Mentions - PennyStockTweets
Twitter View EXEL Stock Mentions - Twitter Invest Hub View EXEL Investment Forum News - Investor Hub
Yahoo View EXEL Stock Mentions - Yahoo! Message Board Seeking Alpha View EXEL Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for EXEL - SECform4.com Insider Cow View Insider Transactions for EXEL - Insider Cow
CNBC View EXEL Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for EXEL - OTC Markets
Yahoo View Insider Transactions for EXEL - Yahoo! Finance NASDAQ View Institutional Holdings for EXEL - NASDAQ


Stock Charts

FinViz View EXEL Stock Insight & Charts - FinViz.com StockCharts View EXEL Investment Charts - StockCharts.com
BarChart View EXEL Stock Overview & Charts - BarChart Trading View View EXEL User Generated Charts - Trading View




Latest Financial News for EXEL


Exelixis to Release Second Quarter 2018 Financial Results on Wednesday, August 1, 2018
Posted on Tuesday July 17, 2018

Exelixis, Inc. (EXEL) announced today that its second quarter 2018 financial results will be released on Wednesday, August 1, 2018 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. To access the webcast link, log onto www.exelixis.com and proceed to the News & Events / Event Calendar page under the Investors & Media heading.


See what the IHS Markit Score report has to say about Exelixis Inc.
Posted on Monday July 16, 2018

Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 12. Over the last one-month, outflows of investor capital in ETFs holding EXEL totaled $22 million.


Top 5 Biotech Stocks for 2018
Posted on Wednesday July 11, 2018

Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.


Why Analysts are Mostly Positive On Acceleron Pharma
Posted on Monday July 09, 2018

After Acceleron’s and Celgene’s (CELG) June 28 announcement of the Phase 3 MEDALIST trial results, Acceleron stock started rising, recording ~42.79% growth on June 29 to close at $48.52. Celgene and Acceleron Pharma conducted the MEDALIST trial to evaluate the safety and efficacy of luspatercept for the treatment of individuals with myelodysplastic syndrome and chronic anemia who are not eligible or are intolerant to erythropoietin-stimulating agents.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.